Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership
Start Date
November 1, 2016
End Date
October 31, 2021
Administered By
Duke Cancer Institute
Awarded By
The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership
Start Date
November 1, 2016
End Date
October 31, 2021